In this review, the authors described menin and CD47 as targets for treatment of AML. The references are well cited and contents are well written.

I have several minor comments:

1. Further detailed editing of the manuscript is necessary. There are several minor points for edition, such as
   - Gene names are to be italicized.
   - Gene names are to be written in a uniform format. For example, FLT3-ITD is a more standard writing, but in the manuscript, occasionally other formats are seen. In addition, NPM1 mutation and NPM1c are both used in the manuscript.
   - KMT2A is to be used throughout the manuscript; somewhere MLL is still used.
   - MEIS1 and Meis1 are both visible in the manuscript.
2. At the end of "Menin Biology: A Short Introduction", the authors regarded NPM1 mutation and wildtype or low allelic ratio of FLT3-ITD as favorable prognosis. However, in new ELN2022 guideline (*Blood* (2022) 140 (12): 1345–1377.), FLT3-ITD allelic burden is no longer considered in risk stratification. I suggest the author use this newly published guideline.
3. Figure 1 is well illustrated, but I suggest HOX and MEIS1 be separated. The current illustration shows HOX followed by MEIS1, and is likely to mislead the readers that these two genes are located in the same chromosome.
4. At the beginning of "7. Targeting CD47 in Acute Myeloid Leukemia", the authors described "CD47 is highly expressed in AML cells including leukemia stem cells with approximately 25-30% of patients having high levels of expression". This sentence is confusing. Please write a clearer statement.